Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis.
OBJECTIVE
To evaluate the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis.


METHODS
30 dogs with atopic dermatitis examined at a veterinary dermatology referral practice for treatment with allergen-specific immunotherapy.


METHODS
A catheter was placed in a vein in each dog. Dogs were constantly observed throughout the procedure. Allergen extracts were administered in increasing concentrations every 30 minutes for 6 hours to a maintenance concentration of 20,000 protein nitrogen units/ml. Epinephrine, oxygen, and emergency treatment were available as needed.


RESULTS
In 22 (73%) dogs, rush immunotherapy safely replaced the prolonged induction period (15 weeks) of weekly injections that consists of increasing concentrations of allergen extract. In 7 (23%) dogs, the induction period was abbreviated to 4 weeks. Of the 8 dogs that developed problems during rush immunotherapy, increased pruritus necessitated premature cessation of rush immunotherapy in 7, and 1 developed generalized wheals. Oral administration of prednisolone (1 mg/kg of body weight) resulted in resolution of adverse effects in all 8 dogs.


CONCLUSIONS
Rush immunotherapy performed by personnel at a veterinary hospital is a safe method for treatment of dogs with atopic dermatitis.
Mueller
R S
RS
Animal Skin and Allergy Clinic, Mount Waverley, VIC, Australia.
Bettenay
S V
SV
D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000276:immunology / Q000628:therapy / Q000662:veterinary*; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods / Q000662:veterinary*; D004283:Dog Diseases / Q000276:immunology* / Q000628:therapy; D004285:Dogs; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology
D000485:Allergens; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011239:Prednisolone